The goal of this project is to develop a liquid crystal-based sensor that can detect and measure nitric oxide in exhaled breath. The sensor technology is based on a broadly applicable detection platform that exploits the sensitivity of liquid crystals (LCs) to the nanoscopic changes in the structure of surfaces. Many attributes of this LC technology suggest that it offers exciting potential for clinical applications. It can be used to fabricate low cost, highly specific sensor elements that analyze chemicals in real time (response in ~ 10 seconds), are highly sensitive (can detect 1 ppb or less in vapor phase), provide a wide dynamic range (4 orders of magnitude), offer format flexibility, and are easily customized to detect selected compounds. Because the technology does not require expensive or complex instrumentation, or highly skilled personnel to operate the equipment, it is ideally suited as a cost-effective and reliable approach for breath monitoring. The outcome of this Phase I proposal will be a sensor element that can detect and measure ppb levels of exhaled nitric oxide. The LC-based sensor elements are small (<1cm in size) and will be integrated with electronics to analyze and report analyte concentrations. Our intended product will display a readout of the collected data to the user. Such a product will enable self- monitoring by asthmatics and play a key role in disease management.

Public Health Relevance

The goal of this project is to develop a liquid crystal-based sensor that can detect and measure nitric oxide in exhaled breath. The sensor technology is based on a broadly applicable detection platform that exploits the sensitivity of liquid crystals (LCs) to the nanoscopic changes in the structure of surfaces. Many attributes of this LC technology suggest that it offers exciting potential for clinical applications. It can be used to fabricate low cost, highly specific sensor elements that analyze chemicals in real time (response in ~ 10 seconds), are highly sensitive (can detect 1 ppb or less in vapor phase), provide a wide dynamic range (4 orders of magnitude), offer format flexibility, and are easily customized to detect selected compounds. Because the technology does not require expensive or complex instrumentation, or highly skilled personnel to operate the equipment, it is ideally suited as a cost-effective and reliable approach for breath monitoring. The outcome of this Phase I proposal will be a sensor element that can detect and measure ppb levels of exhaled nitric oxide. The LC-based sensor elements are small (<1cm in size) and will be integrated with electronics to analyze and report analyte concentrations. Our intended product will display a readout of the collected data to the user. Such a product will enable self- monitoring by asthmatics and play a key role in disease management.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL095167-01
Application #
7600280
Study Section
Special Emphasis Panel (ZRG1-RES-E (10))
Program Officer
Smith, Robert A
Project Start
2009-03-01
Project End
2011-02-28
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
1
Fiscal Year
2009
Total Cost
$199,952
Indirect Cost
Name
Platypus Technologies, LLC
Department
Type
DUNS #
118040364
City
Madison
State
WI
Country
United States
Zip Code
53711
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Basu, Sanjay; Sussman, Jeremy B; Berkowitz, Seth A et al. (2018) Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S. Diabetes Care 41:586-595
Leigh, Adam; McEvoy, John W; Garg, Parveen et al. (2018) Coronary Artery Calcium Scores and Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers: MESA. JACC Cardiovasc Imaging :
El Khoudary, Samar R; Ceponiene, Indre; Samargandy, Saad et al. (2018) HDL (High-Density Lipoprotein) Metrics and Atherosclerotic Risk in Women. Arterioscler Thromb Vasc Biol 38:2236-2244
Raffield, Laura M; Ellis, Jaclyn; Olson, Nels C et al. (2018) Genome-wide association study of homocysteine in African Americans from the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Coronary Artery Risk in Young Adults study. J Hum Genet 63:327-337
Bhambhani, Vijeta; Kizer, Jorge R; Lima, Joao A C et al. (2018) Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail 20:651-659
Floyd, J S; Sitlani, C M; Avery, C L et al. (2018) Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics J 18:127-135
Hastert, T A; de Oliveira Otto, M C; LĂȘ-Scherban, F et al. (2018) Association of plasma phospholipid polyunsaturated and trans fatty acids with body mass index: results from the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond) 42:433-440
Talluri, Rajesh; Shete, Sanjay (2018) An approach to estimate bidirectional mediation effects with application to body mass index and fasting glucose. Ann Hum Genet 82:396-406
Hajek, Catherine; Guo, Xiuqing; Yao, Jie et al. (2018) Coronary Heart Disease Genetic Risk Score Predicts Cardiovascular Disease Risk in Men, Not Women. Circ Genom Precis Med 11:e002324

Showing the most recent 10 out of 369 publications